



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION

Common Name	CD74-DOX (ADC),hLL1,hLL1-DOX (ADC),MEDI-115, Unconjugated mAb
Conjugate	Unconjugated
Synonyms	DHLAG
Applications	ELISA, Flow Cyt
Recommended Dilutions	ELISA 1:5000-10000, Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Host Species	Humanized
IgG type	IgG1(K97R)
Reactivity	Human
Target	CD74
Uniprot ID	P04233
Description	Anti-CD74(milatumzumab biosimilar) mAb
Delivery	In Stock
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. Our unconjugated biosimilar monoclonal antibodies (mAbs) are based on the sequences outlined in relevant patents or scientific publications. These antibodies are in their native, unconjugated form, meaning they do not contain any payload or therapeutic agent attached. They are designed for use in research and development, and their performance has been tested as standalone molecules through comprehensive QC tests.
Usage	Research use only
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.






Figure 1. Flow cytometry analysis with 15µg/mL Anti-CD74(milatuzumab biosimilar) mAb (BME100170) on Expi293 cells transfected with Human CD74 protein (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram).

**Anti-CD74(milatuzumab biosimilar) mAb ELISA**  
0.2 µg of Human CD74, hFc tagged protein per well




Figure 2. ELISA plate pre-coated by 2 µg/mL (100 µL/well) Human CD74 (73-296) Protein, hFc Tag(PME100642) can bind Anti-CD74(milatuzumab biosimilar) mAb(BME100170) in a linear range of 0.64-16 ng/mL. In order to specifically detect BME100170, mouse anti-human Fab-specific antibody was used as detection antibody.






Figure 3. Flow cytometry analysis of antigen binding of anti-human CD74 mAb(BME100170).  
(A) BME100170 does not bind to 293T cells that do not express CD74.  
(B) A clear peak shift of BME100170 was seen compared to the control when incubated with CD74-expressing Raji cells, indicating strong binding of BME100170 to CD74. Antibodies were incubated at 5 µg/mL.

